Skip to main content
Year archive

NEURIZON THERAPEUTICS LIMITED — 2025 filings

All 77 regulatory filings released by NEURIZON THERAPEUTICS LIMITED (NUZ) in 2025, sourced directly from the official regulator.

77 Filings
2025 Period
2025 filings (77)
Filing Released Lang
Application for quotation of securities - NUZ 5 pages 17.0KB
Share Issue/Capital Change
2025-12-30 English
New Funding Secured for HEALEY ALS Platform Trial 11 pages 457.9KB
Capital/Financing Update
2025-12-22 English
Equity Raising Presentation 53 pages 3.5MB
Investor Presentation
2025-12-22 English
Proposed issue of securities - NUZ 9 pages 30.8KB
Capital/Financing Update
2025-12-22 English
Proposed issue of securities - NUZ 6 pages 22.4KB
Capital/Financing Update
2025-12-22 English
Notice under s708AA(2)(f) 2 pages 250.1KB
Capital/Financing Update
2025-12-22 English
Application for quotation of securities - NUZ 6 pages 18.5KB
Share Issue/Capital Change
2025-12-22 English
Section 708A Cleansing Statement 2 pages 241.6KB
Capital/Financing Update
2025-12-22 English
Trading Halt 2 pages 373.0KB
Capital/Financing Update
2025-12-18 English
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial 2 pages 252.9KB
Regulatory Filings
2025-12-10 English
Neurizon Completes GMP Tablet Registration Batches 2 pages 246.6KB
Capital/Financing Update
2025-12-03 English
Amended Constitution 63 pages 914.4KB
Governance Information
2025-12-02 English
Elanco executive appointed as Board Observer 2 pages 188.8KB
Board/Management Information
2025-11-25 English
Chairman's AGM Address 3 pages 263.3KB
AGM Information
2025-11-25 English
AGM Presentation 24 pages 2.7MB
AGM Information
2025-11-25 English
Results of Annual General Meeting 4 pages 439.4KB
Declaration of Voting Results & Voting Rights Announcements
2025-11-25 English
Neurizon to present Q1 FY2026 Results 24 pages 2.7MB
Interim / Quarterly Report Q1 2026
2025-10-30 English
Application for quotation of securities - NUZ 6 pages 18.3KB
Share Issue/Capital Change
2025-10-30 English
Section 708A Cleansing Statement 2 pages 343.1KB
Capital/Financing Update
2025-10-30 English
Appendix 4C & Quarterly Update 12 pages 729.3KB
Interim / Quarterly Report Q1 2026
2025-10-28 English
Notice of Annual General Meeting/Proxy Form 26 pages 719.2KB
AGM Information
2025-10-22 English
Australian Patent Granted for NUZ-001 2 pages 395.6KB
Regulatory Filings
2025-10-20 English
Quarterly Shareholder Update Webinar - Q1 FY2026 1
Investor Presentation
2025-10-19 English
Neurizon to Present Poster Data at 2025 NEALS Annual Meeting 7 pages 3.5MB
Investor Presentation
2025-10-09 English
Neurizon Commences Trading on OTCQB Venture Market 3 pages 407.1KB
Capital/Financing Update
2025-10-07 English
Proposed issue of securities - NUZ 5 pages 17.4KB
Share Issue/Capital Change
2025-10-07 English
FDA Lifts Clinical Hold on NUZ-001 2 pages 448.4KB
Regulatory Filings
2025-10-05 English
Notification regarding unquoted securities - NUZ 7 pages 22.2KB
Share Issue/Capital Change
2025-09-30 English
Section 708A Cleansing Statement 2 pages 341.6KB
Capital/Financing Update
2025-09-23 English
Application for quotation of securities - NUZ 5 pages 16.9KB
Share Issue/Capital Change
2025-09-22 English
Neurizon Raises $5m via Institutional Placement 2 pages 419.2KB
Capital/Financing Update
2025-09-17 English
Proposed issue of securities - NUZ 5 pages 19.0KB
Capital/Financing Update
2025-09-17 English
R&D Tax Incentive Advance & Overseas Finding Approval 2 pages 325.8KB
Capital/Financing Update
2025-09-17 English
Trading Halt 2 pages 285.6KB
Capital/Financing Update
2025-09-15 English
Change of AGM Date 1 page 263.4KB
AGM Information
2025-08-31 English
Appendix 4E and 2025 Annual Report 76 pages 3.7MB
Annual Report FY 2025
2025-08-25 English
Appendix 4G and Corporate Governance Statement 25 pages 833.8KB
Regulatory Filings
2025-08-25 English
Neurizon to present Q4 updates to Shareholders 32 pages 2.6MB
Interim / Quarterly Report Q4 2025
2025-08-25 English
NUZ-001 Shows Long-Term Safety and Efficacy Signals in OLE 24 pages 3.8MB
Investor Presentation
2025-08-19 English
Notice of Shareholder Update Webinar 2 pages 349.3KB
Regulatory Filings
2025-08-19 English
FDA Review Timeline Extended for NUZ-001 IND Clinical Hold 2 pages 310.0KB
Regulatory Filings
2025-08-14 English
Neurizon Commences Manufacture of First Registration Batch 2 pages 417.5KB
Capital/Financing Update
2025-08-11 English
AGM Date & Director Nominations Closing Date for AGM 1
AGM Information
2025-08-04 English
Neurizon Secures Loan Against 2025 R&D Tax Rebate 2 pages 377.9KB
Capital/Financing Update
2025-07-29 English
Appendix 4C & Quarterly Update 13 pages 1.0MB
Interim / Quarterly Report Q4 2025
2025-07-29 English
Neurizon Submits Clinical Hold Complete Response to FDA 2 pages 439.7KB
Regulatory Filings
2025-07-24 English
Positive feedback from FDA on strategy to lift clinical hold 2 pages 354.5KB
Capital/Financing Update
2025-07-09 English
Neurizon Enters Global Licensing Agreement with Elanco 2 pages 389.2KB
Capital/Financing Update
2025-07-01 English
Invitation to Shareholder Webinar 2 pages 307.7KB
Regulatory Filings
2025-07-01 English
Presentation Materials - Licensing Agreement Webinar 12 pages 1.4MB
Investor Presentation
2025-07-01 English
Neurizon develops liquid formulation of NUZ-001 2 pages 401.4KB
Regulatory Filings
2025-06-25 English
Notification regarding unquoted securities - NUZ 7 pages 23.1KB
Share Issue/Capital Change
2025-06-25 English
NUZ-001 Shows Significant Blood-Brain Barrier Penetration 3 pages 521.0KB
Regulatory Filings
2025-06-19 English
NUZ-001 Shows Promise in a Model of Huntington's Disease 4 pages 1.6MB
Regulatory Filings
2025-06-15 English
Release of Securities from Escrow 1 page 280.4KB
Capital/Financing Update
2025-06-15 English
Change of Registered Office and Principal Place of Business 1
Regulatory Filings
2025-06-01 English
Neurizon to present at Annual ALS Drug Development Summit 27 pages 5.8MB
Investor Presentation
2025-05-13 English
Neurizon to present Q3 FY2025 Results 22 pages 1.7MB
Interim / Quarterly Report Q3 2025
2025-05-05 English
Last Patient Successfully Completes Treatment in OLE Study 3 pages 714.5KB
Regulatory Filings
2025-05-04 English
Appendix 4C & Quarterly Update 14 pages 997.3KB
Interim / Quarterly Report Q3 2025
2025-04-27 English
Notice of Quarterly Shareholder Update Webinar 2 pages 183.8KB
Regulatory Filings
2025-04-23 English
Appointment of Chief Financial Officer 2 pages 375.4KB
Board/Management Information
2025-04-21 English
Leadership team strengthened with strategic appointments 3 pages 208.5KB
Board/Management Information
2025-04-16 English
NUZ-001 Promotes Survival in TDP-43 Challenged NSC-34 Cells 4 pages 7.2MB
Regulatory Filings
2025-04-03 English
NUZ-001 Shows Positive Results in Human 3D Brain Model 4 pages 1.7MB
Regulatory Filings
2025-03-31 English
NUZ-001 shows promising respiratory outcome 4 pages 759.0KB
Capital/Financing Update
2025-03-23 English
Neurizon Commences Initiatives to Lift Clinical Hold 2 pages 358.8KB
Regulatory Filings
2025-03-16 English
FDA Guidance on NUZ-001 IND Application 2 pages 353.2KB
Regulatory Filings
2025-02-16 English
Neurizon to Present Latest Results and Key Updates 23 pages 7.1MB
Interim / Quarterly Report H1 2025
2025-02-16 English
Appendix 4D - Half-year Financial Report - 31 December 2024 25 pages 1.3MB
Interim / Quarterly Report H1 2025
2025-02-16 English
Notice of Company Update Webinar 2 pages 345.4KB
Regulatory Filings
2025-02-10 English
Change of Director's Interest Notices x3 9 pages 748.1KB
Director's Dealing
2025-02-06 English
US Patent granted for NUZ-001 2 pages 387.5KB
Regulatory Filings
2025-02-04 English
Notification regarding unquoted securities - NUZ 7 pages 21.9KB
Share Issue/Capital Change
2025-01-30 English
Appendix 4C & Quarterly Update 10 pages 863.0KB
Interim / Quarterly Report Q2 2025
2025-01-28 English
Neurizon updates on NUZ-001 IND Application 2 pages 308.7KB
Regulatory Filings
2025-01-16 English
Change of Share Registry 2 pages 329.0KB
Regulatory Filings
2025-01-15 English